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ABBREVIATIONS 
 
ACTH  adreno-corticotrop hormone 
ADMA asymmetric dimethylarginine 
AIS  acute ischaemic stroke 
BI  Barthel-index 
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CD40L CD40 ligand 
CNS  central nervous system 
DDAH dimethylarginine dimethylamin-hydrolase  
eNOS  endothelial nitric-oxid synthase 
MCP-1 monocyte chemoattractant protein-1 
hsCRP  high sensitivity C-reactive protein 
ICAM-1 intracellular adhaesion molecule-1 
IL-1   interleukin-1 
IL-6  interleukin-6 
IL-8  interleukin-8 
mRS  modified Rankin scale 
NIHSS National Institute of Health Stroke Scale 
NO  nitric-oxid 
PCT  procalcitonin 
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PRMT  protein methyl-transferase 
S100B  S-100-beta protein 
SDMA symmetric dimethyl-arginine 
SIIDS  stroke-induced immundepression syndrome  
TIA  transient ischaemic attack 
TLR  Toll-like receptor 
TNF-α  tumor necrosis faktor-α 
TOAST Trial of Org 10172 in Acute Stroke Treatment 
tPA  tissue plasminogen activator 
VCAM-1 vascular cell adhaesion molecule-1 
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I. INTRODUCTION 
 
 
I/1. The epidemiology of ischaemic stroke 
According to the World Health Organization (WHO) definition, stroke is a “rapidly developing 
clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 
hours or longer or leading to death, with no apparent cause other than of vascular origin”. Stroke 
is the leading cause of minor and major long-term disability in adults and only 10% of the 
patients are able to live their previous way of life. 
I/2. The prevalence of post-stroke infections 
Not only the severity of the stroke itself, but the acute and chronic medical and neurological 
complications contribute to the mortality and poor functional outcome. Post-stroke infection is 
defined as an infection that occurs during the acute phase (0–7 days) of stroke. Post-stroke 
infections worsen the functional outcome and raise the mortality. The meta-analysis of 87 
studies showed that infections affect approximately 30% of patients with acute stroke.  
I/3. Preventive antibiotic treatment in acute stroke 
Five randomised, placebo-controlled studies have examined the effect of preventive antibiotic 
treatment in stroke in recent years. 
The Early Systemic Prophylaxis of Infection After Stroke (ESPIAS) study examined the effect 
of levofloxacin prophylaxis in patients with ischemic or hemorrhagic stroke. The study was 
stopped because levofloxacin did not decrease the rate infections.  
Another antibiotic trial was the Preventive ANtibacterial THERapy in acute Ischemic Stroke 
(PANTHERIS). Patients were randomised to receive either intravenous moxifloxacin or 
placebo. Moxifloxacin decreased the rate of the post-stroke infections significantly but did not 
affect mortality and functional outcome. 
In The Mannheim Infection in Stroke Study (MISS), patients received mezlocillin plus 
sulbactam. The combined antibiotic treatment decreased the rate of infection; and there was a 
trend of improved clinical outcome.  
The results of the Preventive Antibiotics in Stroke Study (PASS) showed that although 
ceftriaxone therapy significantly prevented infections, it neither reduced mortality nor 
influenced the functional outcome. 
The STROKE-INF study was published in 2015. Antibiotic prophylaxis did not decrease the 
rate of pneumonia and did not affect mortality and functional outcome. Thus, III.B. level 
evidences suggest that administration of preventive antibiotic treatment is not recommended in 
acute post-stroke period.  
 
8 
 
I/4. Central nervous system-injury induced immunodepression syndrome (CIDS) 
After cerebral ischemia, the disruption of the blood-brain barrier allows leukocytes, including 
neutrophils, macrophages and lymphocytes to enter the damaged brain tissue and brain antigens 
to enter peripheral circulation. This process may expose brain epitopes which are normally 
“invisible” to the immune system and thus may promote priming and activation of lymphocytes 
reactive to central nervous system (CNS) antigens. 
This crosstalk between the CNS and the immune system is partly mediated by the sympathetic 
nervous system, the hypothalamic-pituitary-adrenal axis (HPA) and the vagus nerve. The 
inflammatory cytokine production caused by brain tissue necrosis stimulates neurones in the 
paraventricular nuclei of the hypopthalamus (PVN) and leads corticotropin-releasing factor 
(CRF) production. Overactivation of the adrenergic system results in the release of 
catecholamines and corticosteroids. This model is supported by studies showing that increased 
serum cortisol and catecholamine levels in patients with acute stroke are independent predictors 
of mortality in stroke patients. The secretion of cortisol is regulated by ACTH, but in patients 
suffering from stroke, the level of cortisol is not related to the serum level of ACTH but rather 
to the IL-6. The increased amount of cortisol results in immunosuppression, which can increase 
the chance of infection. Due to the immunodepression and reduced pro-inflammatory immune 
responses, the susceptibility for infection is increased; indeed, post-stroke infection plays a 
major role in stroke-related mortality. On the other hand, CIDS may protect against damaging 
autoimmune responses elicited by exposed CNS antigens. This mechanism is called CNS-
injury-induced immunodepression syndrome.  
 
II. THE IMPACT OF POST-STROKE INFECTIONS ON THE OUTCOME OF 
ISCHEMIC STROKE 
II/1. Aims of the study 
First, we prospectively investigated the frequency of post-stroke infections in patients admitted 
with acute ischaemic stroke and their effect on functional outcomes and mortality. We also 
evaluated the etiology of ischemic stroke, the demographic data and co-morbidity of the 
patients, and their impact on post-stroke infections and outcomes.  
II/2. Subjects and Methods 
One hundred and six patients with acute ischemic stroke were enrolled within 6 hours after the 
onset of symptoms. Hemorrhagic stroke, infection and/or fever within <4 weeks, elevated white 
blood cell counts (WBC) and/or elevated PCT level on admission were exclusion criteria. 
Severity of stroke was measured by the National Institute of Health Stroke Scale (NIHSS).  
Medical history and demographic data were collected. Etiology of stroke was defined by 
TOAST criteria. Endpoints were appearance of post-stroke infection, mortality and functional 
outcome on the 28th day assessed by the modified Barthel index. Post-stroke infections were 
defined as infections that emerge within the 1st week after admission. Statistical analysis was 
performed by SPSS 16.0 software. 
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II/3. Results 
 
II/3. a. Demographic data and concomittant diseases 
The mean age of patients was 69.8 year, and women were 8 years older than men. Hypertension 
was the most frequent risk factor in both gender. The rate of smokers was five-times higher in 
men than women; on the other hand, the frequency of cardiac risk factors (atrial fibrillation 
and/or prostathic valve) were twice more common in women (Table 1). 
Table 1. Demographic data and concomittant diseases 
  Patients Women Men 
N 108 57 51 
Age (mean±SD) 69.79 (±12.01) 73.8 (±12.3) 65.77 (±10.26) 
Hypertension (%) 71.6 68.2 76.5 
Diabetes mellitus (%) 15.6 14 17.6 
Smoking (%) 20.2 7 35.3 
Previous stroke/TIA (%) 19.3 22.8 15.7 
Cardiac risk factor (%) 37.6 49.1 25.5 
Obesity (%) 12.8 14 11.8 
II/3. b. The severity and outcome of acute ischemic stroke 
The severity of stroke based on the NIHSS score at admission did not differ between men and 
women. The 7-day and emission NIHSS were significantly better in men than women. The 28-
day functional outcome did not differ significantly between men and women (Table 2)  
Table 2. The severity and functional outcome of acute ischemic stroke  
  Mean (± SD) Women Men 
P-value 
(women/men) 
NIHSS1 11.01 (±5.63) 11.9 (±5.52) 10 (±5.64) 0.887 
NIHSS7  9.4 (±7.03) 10.8 (±8.04) 7.3 (±4.62) 0.002 
NIHSS emission 10.39 (±13.96) 12.5 (±17.5) 7.32 (±12.5) 0.081 
28-day BI 68.6 (±38.53) 64.7 (±34.9) 72.1 (±28.35) 0.225 
Mann-Whitney U test; NIHSS1: National Institute of Health Scale score on day 1; NIHSS7: National Institute of 
Health Scale score on day 7; NIHSS emission: National Institute of Health Scale score on the day of emission;28-
day BI:Barthel index on the 28th day after the onset of stroke 
II/3. c. Classification of patients according to the TOAST criteria 
Fifty-two percentage of patients suffered from cardioembolic stroke, 32% of patients had 
ischaemic stroke related to large-vessel atherosclerosis, and 16% of patients were admitted with 
lacunar stroke. Patients with cardio-embolic stroke were significantly older than patients in the 
other two groups (Table 3). The functional outcomes of stroke were significantly better in 
lacunar stroke compared with strokes from large-vessel atherosclerosis and cardio-embolic 
origin; there were no differences between the latter two groups (Table 3). 
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Table 3. Age of patients and severity of stroke according to the TOAST criteria  
  
Large-vessel 
athero-sclerosis 
Cardio-
embolic 
Lacunar 
stroke 
P-value 
large-vessel vs. 
cardio-embolic 
P-value 
large-vessel vs. 
lacunar 
P-value 
cardioemb. vs. 
lacunar 
age 68.7±10.03 77.3±9.48 66.4±10.25 0.003 0.814 0.001 
NIHSS1 12.65±5.887 14.07±4.89 6.89±3.71 0.506 0.003 0.000 
BI 28 day  60±30.1 61.3±36.68 85.3±19.2 0.694 0.024 0.020 
Mann-Whitney U test; NIHSS1: National Institute of Health Scale Score on day 1; BI 28 day: Barthel index on the 
28th day after stroke onset 
II/3. d. Post-stroke infections and mortality 
 
Twenty-one percentages of our patients suffered from post-stroke infection affecting 8% of men 
and 34% of women. Cardioembolic stroke and obesity showed the strongest correlation with 
the appearance of post-stroke infections. Twenty-one patients (4 men and 17 women) died: 
mortality significantly correlated with the severity of stroke. Occurence of infections 
significantly correlated with the age of patients, the NIHSS score on admission, the 7th day 
NIHSS score and NIHSS score at discharge, but did not correlate with functional outcome on 
the 28th day. Mortality showed correlation with the appearance of post-stroke infection.  
 
II/4. Discussion 
 
The mean age of the 106 patients admitted with acute ischaemic stroke weas 69.7 year, and 
women were 8 years older than men. Hypertension was the most frequent risk factor in both 
gender groups. The rate of smokers was 5-times higher in men than women, but cardiac risk 
factors appeared twice in women (25% vs 50%). Strokes of large-vessel disease and 
cardioembolic origin were significantly more severe than lacunar stroke. The severity of stroke 
had a crucial part in mortality. Post-stroke infections - affecting 20% of patients - significantly 
correlated with age, obesity, severity of stroke and cardio-embolic origin. In case of infections, 
the mortality was significantly higher. 
Hospital-based data in almost 20000 stroke patients obtained from the Swedish Stroke Registry 
showed that the incidence of atrial fibrillation increases with age, and women were 4 years older 
than men. Strikingly, our male patients were 10 years younger and female patients 5 years 
younger than Swedish patients with stroke. Data from the Swedish registry showed that the 
frequency of cardio-embolic stroke did not differ according to gender. This is substantively 
different data what we observed: the rate of cardioembolic stroke was twice more frequent 
among women than men in our cohort. In the Framingham Heart study, age was one of the 
strongest risk factor for having atrial fibrillation. Since our women patients were 8 years older 
than men, it can be an explanation, why the rate of cardioembolic stroke was much higher 
among women. Twenty percents of our patients had post-stroke infection similar to published 
data. Infections affected women four-times more than men, and appearance of infection 
significantly correlated with mortality. Since stroke with cardioembolic origin was twice more 
frequent among women, and it was the most severe, it may explain, why the mortality of women 
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was four-times higher. Among patients, who survived the acute post-stroke period, post-stroke 
infections did not influence the 28th day functional outcomes.  
 
 
III. BIOMARKER MEASUREMENTS AND THE FUNCTIONAL OUTCOME OF 
ISCHAEMIC STROKE 
 
III/1. Aims of the study 
 
Here, the temporal profile of 8 biomarkers, which contribute to thrombo-inflammatory process, 
endothelial dysfunction and systemic immune responses, or correlate with infarct size were 
prospectively investigated in 77 patients with acute ischaemic stroke. We examined their 
baseline levels, their concentration 72 hours later, the temporal change of the biomarker 
concentration, and the predictive potential of all these factors for stroke outcomes. The primary 
endpoints were mortality, occurance of post-stroke infection and functional outcome on the 28th 
day. We examined the simultaneous relation of the measured biomarkers to the outcomes 
(death, infection, function) using multiple regression, and examined the regression models’ 
ability to predict the different outcomes. 
 
III/2. Subjects and Methods 
Seventy-six patients with acute ischemic stroke were enrolled within 6 hours after onset of 
symptoms: medical history was collected; standard laboratory tests, 12-lead ECG, and cerebral 
CT were performed. Infection and/or fever within <4 weeks and elevated white blood cell 
counts on admission were exclusion criteria. Severity of stroke was measured by the National 
Institute of Health Stroke Scale (NIHSS). NIHSS was measured daily till day 7. The etiology 
of stroke was defined by the TOAST criteria. The outcome was assessed by the modified 
Barthel index (BI) on the 28th day. Thirteen patients received intravenous thrombolysis. The 
size of infarct was assessed by the concentration of S100-beta protein in the serum (S100B). 
Levels of 7 additional biomarkers were measured that may all contribute to thrombo-
inflammation, endothelial dysfunction and systemic/local inflammation: hypersensitive C-
reactive protein (hsCRP), CD40-ligand (CD40L), tissue plasminogen activator (tPA), 
monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and P-
selectin. Baseline and 72-hour levels were measured and the change of concentrations was 
calculated.  
Two control populations were used: 44 patients with significant carotid stenosis (70-100%) 
determined by Duplex scan sonography but without acut vascular events, to determine if 
concentrations are related to the acute ischemic event itself or are inherent to the pre-existing 
atherosclerosis; and 66 patients with Parkinson disease as non-vascular controls.  
Next, we prospectively analysed the rate of infectious complications during hospitalization and 
its relationship with the concomittant diseases and demographic factors. We analyzed, whether 
the severity of stroke measured by NIHSS score and serum S100 beta titer influence the 
prevalence of post-stroke infections.  Finally, we simultaneously considered the 8 biomarkers 
(hsCRP, S100B, CD40L, tPA, MCP-1, IL-8, IL-6, P-selectin), using their absolute 
concentrations at different time points (values at baseline and at 72 hours) and the change from 
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baseline to 72 hours as covariates. Their association with post-stroke infections, death and 
functional outcome were investigated. We applied multiple regression methods, relating 
biological biomarkers combined with demographic data and co-morbidities to the considered 
outcomes. For the analysis of NIHSS at day 7, we also added the value of NIHSS at day 1 as 
covariate, and assessed the ability of the models to predict each outcome. 
III.3. Biomarkers 
III/3 a. S100beta protein  
S100B protein is a member of a group of small Ca2+-binding modulators. Members of this 
protein family have been implicated in the Ca2+-dependent regulation of a variety of 
intracellular activities, such as protein phosphorylation, enzyme activities, cell proliferation and 
differentiation, intracellular Ca2+ homeostasis, inflammation, and protection from oxidative cell 
damage. Several studies have shown that serum S100B levels measured in serum samples taken 
more than 24 h after stroke onset demonstrate a strong correlation with the degree of 
neurological deficit and the final infarct volume. One metaanalysis published in 2012 showed 
a strong correlation between the brain tissue damage certified by radiological investigations and 
the value of S100B 48-72 hours after brain tissue damage. Therefore, we used this marker to 
measure the infarct volume indirectly.  
III/3. b. hsCRP 
High sensitivity C-reactive protein is a member of acute phase proteins. Recently, it was shown 
that elevated hsCRP levels independently predicted future stroke and transient ischemic attack 
in elderly.  More than 20 prospective studies of distinct cohorts have demonstrated that 
increased hsCRP concentrations are associated with an increased risk of cardiovascular events 
after multivariate adjustment for traditional risk factors. 
III.3. c. Interleukin 6 (IL-6) 
IL-6 promotes the expression of adhesion molecules, activation of leukocytes, and results in a 
prothrombotic state. The increased concentration of IL-6 in the serum is a characteristics of 
acute ischaemic stroke, and the level of IL-6 correlates with the infarct volume and the outcome 
of stroke.  
III./3. d. Monocyte-chemoattractant protein-1 (MCP-1) 
MCP-1 is a member of chemokines that control the migration of neutrophils, lymphocytes, 
antigen-presenting cells including dendritic cells, and cells of the monocyte/macrophage 
lineage. There is strong evidence that MCP-1 is involved in the recruitment of both monocytes, 
macrophages and activated lymphocytes into the CNS. 
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III.3. e. Soluble CD40 ligand (sCD40L) 
Soluble CD40 ligand is a transmembrane protein with pleiotrop effects expressed by antigen-
presenting cells. The engagement of the CD40 and CD40 ligands regulates a wide spectrum of 
molecular and cellular processes, including the initiation and progression of cellular and 
humoral adaptive immunity.  
III/3. f. P-selectin 
P-selectin is produced by both platelets and endothelial cells, and mediates early inflammatory 
cell adhesion. The ligand of P-selectin is expressed mainly by polymorphonuclear cells and 
monocytes. Such intercellular communication results in responses by all these cell populations: 
leukocyte invasion, enhanced platelet aggregation and thromboxane release. Experimental data 
showed that anti-P-selectin monoclonal antibody therapy significantly decreases the leukocyte 
infiltration to brain tissue and the volume of the infarction in case of cerebral media artery 
occlusion. 
III/3. g. Tissue plasminogen activator (tPA) 
Tissue plasminogen activator is a protein involved in the breakdown of blood clots. It is a serine 
protease found on endothelial cells. As an enzyme, it catalyzes the conversion of plasminogen 
to plasmin, the major enzyme responsible for clot breakdown. Therapy with recombinant tPA 
in selected patients with acute ischaemic stroke is I.A level of evidence. 
III.3. h. Interleukin-8 (IL-8) 
Interleukin-8 induces the migration and phagocytosis of leukocytes. Experimental data showed 
that IL-8 receptor blocker reparixin decreased the brain infarct volume, and ameliorated the 
neurological outcome in case of middle cerebral artery occlusion.  
III/4. Results 
III/4. a. Biomarker concentrations in the hyperacute phase of ischemic stroke (within 6 hours) 
Biomarkers in the sera were examined within 6 hours after the onset of acute ischemic stroke: 
systemic level of all biomarkers but IL-8 were higher compared to both control groups, PD and 
significant carotid stenosis. Concentrations were also higher in patients with carotid stenosis 
compared to PD, except P-selectin.  
III/4. b. Temporal profile of biomarkers in the acute phase of ischemic stroke 
Changes in biomarker levels during the acute phase of ischemic stroke were also examined 
(within 6, 24 and 72 hours). Three temporal profiles were observed: 
(i):  elevation at 6 hours with additional significant increase by 72 hours (IL-6, P-selectin)  
(ii) elevation at 6 hours and significant decline thereafter (IL-8) 
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(iii)  decreasing value by 24 hours and constant elevation thereafter by 72 hours (tPA, 
 CD40L and MCP-1), but this elevation was not significant. 
III/4. c. Correlation with the size of infarct 
To evaluate the infarct size, we measured the concentration and temporal change of S100B int 
he serum, and correlated its concentration with levels of biomarkers. 
(i) Levels of hsCRP positively correlated with S100B level at any timepoint and the 
 changes of its value.  
(ii) Two other biomarkers showed correlation with S100B concentrations: both baseline and 
72-hour IL-6 level correlated with S100B levels at 72 hours. The 72-hour IL-6 values 
correlated with the change of S100B.  
(iii) Concentration of IL-8 at 72 hours positively correlated with change of S100B titers. 
(iv) Baseline P-selectin concentration correlated with the change of S100B titers (Table 4).  
Table 4. Correlation of S100Bconcentration reflecting the size of infarct with concentration 
of biomarkers 
  
Biomarkers 
S100B 
6 h 
P-value 
72 h 
P-value 
Δ 
P-value 
hsCRP 
                 
                  
6 hour 
72 hour 
 
0.06 
≤0.001 
≤0.001 
0.06 
≤0.001 
0.005 
0.40 
0.003 
0.11 
tPA     
6 hour 
72 hour 
 
0.22 
0.36 
0.88 
0.06 
0.23 
0.80 
0.93 
0.93 
0.25 
P-selectin 
6 hour 
72 hour 
 
0.15 
0.84 
0.34 
0.50 
0.25 
0.91 
0.04 
0.19 
0.15 
MCP-1 
6 hour 
72 hour 
 
0.51 
0.31 
0.10 
0.17 
0.66 
0.10 
0.95 
0.45 
0.43 
IL-8 
6 hour 
72 hour 
 
0.86 
0.08 
0.21 
0.10 
0.36 
0.16 
0.48 
0.02 
0.68 
IL-6 
6 hour 
72 hour 
 
0.09 
0.42 
0.80 
0.003 
0.02 
0.35 
0.19 
0.04 
0.16 
CD40L 
6 hour 
72 hour 
 
0.65 
0.65 
0.05 
0.55 
0.32 
0.70 
0.30 
0.07 
0.19 
Significance levels determined by Spearman’s non-parametric correlations are shown.  : change of 
concentration between post-stroke 6 and 72 hours 
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III/4. d. Biomarker levels according to TOAST criteria 
It was ascertained that: 
 (i) None of the biomarker level differed significantly between the patients with 
large-vessel stroke and cardioembolic strokes at any time-points.  
 (ii) Baseline IL-6 level and 72-hour hsCRP and S100B values significantly differed 
between lacunar stroke and both large-vessel and cardioembolic stroke patients. Similarly, the 
72-hour P-selectine level in large-vessel and cardioembolic group was signifiantly higher than 
the values measured in lacunar stroke cases.  
III/4. e. Correlation with post-stroke infection and death  
Next, we examined, which biomarker level or its change were associated with post-stroke 
infection and death.  
Biomarker levels correlated with mortality: 
, (i) baseline and 72-hour hsCRP value and its change 
(ii)  the change in the level of P-selectine and CD40L between 6 and 72 hours  
(iii) baseline levels of IL-6 and IL-8 
(iv) baseline and 72-hour levels of S100B 
Biomarker levels correlated with post-stroke infections: 
(i) levels of hsCRP measured at 72 hours and its changes between the two time-
points 
(ii)  changes of P-selectine levels 
(iii) baseline and 72-hour levels of IL-6 and S100B and their changes 
 
III/4.f. Regression analysis 
For the three outcomes (death, post-stroke infections and 28th-day functional outcome), we 
established a regression model to relate each outcome to the measured biomarkers, and in order 
to control for possible confounders. We simultaneously considered the 8 biomarkers using their 
values at baseline, at 72 hours and the change from baseline to 72 hours as covariates. In 
addition, demographic/comorbidity variables were also included: age, sex, smoking, obesity 
(BMI), and diabetes. For the analysis of NIHSS at day 7, we also added the value of NIHSS at 
day 1 as covariate. 
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Outcome 1: death:  
(i) each additional year of age increased the odds by 31%;  
(ii) each unit of hsCRP at baseline increased the odds by 7%;  
(iii) each 100 units of IL-6 at baseline increased the odds by 9‰ 
Outcome 2: post-stroke infections:  
(i) female sex increased the odds on average by a factor of 15.3;  
(ii) elevation in P-selectin concentration between 6 and 72 hours by a factor of 22.7;  
(iii) each additional 100 units of IL-6 at 72 hours by 4‰.  
Outcome 3: NIHSS score by day 7 was increased:  
(i) with 0.9 points on average by each NIHSS point measured on day 2;  
(ii) with 2.5 points, when baseline concentration of IL-6 in the peripheral blood was 
measurable;  
(iii) with 2.1 points by obesity;  
(iv) with 0.2 points by each year of age;  
(v) with 1.6 points by male sex.  
 
III/5. Discussion 
Here, we prospectively investigated 8 biomarkers in acute ischemic stroke, which have the 
potential to contribute to thrombo-inflammation in the very early phase, and thus influence the 
outcome.  
Compared to patients with PD, systemic concentration of tPA, P-selectin, MCP-1, IL-8, IL-6 
and CD40L were elevated both within 6 hours after stroke and 72 hours later. Therefore, we 
compared data to patients with severe asymptomatic carotid stenosis, and we also examined the 
temporal profiles.of the biomarkers.  Concentration of all biomarkers but IL-8 was higher 
within 6 hours compared to patients with carotid stenosis, suggesting that increased levels were 
not related to the atherosclerosis per se. However, concentration of tPA, MCP-1, IL-8, IL-6 and 
CD40L were also higher in patients with carotid stenosis compared to PD, indicating that severe 
atherosclerosis was associated with increased systemic concentrations, and stroke resulted in 
an additional acute increase. We used multiple regression to examine, which combination of 
factors could best predict post-stroke infection, death and NIHSS score by day 7; as covariates, 
we considered biological biomarkers and their changes, demographic data and co-morbidities. 
Particularly, change of P-selectin from 6 to 72 hours by one unit increased the incidence of 
post-stroke infections with an OR of 22.7; each 100 units of IL-6 at baseline increased the odds 
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of death by 9‰ and IL-6 level at 72 hours increased the odds of post-stroke infections by 4‰; 
each unit of baseline hsCRP elevated the odds of death by 7%. 
Interestingly, P-selectin, IL-6, and hsCRP contributing to outcomes in our models, all showed 
similar temporal profiles: an additional elevation by 72 hours besides an increased 
concentration on admission (within 6 hours) compared to both patients with carotid stenosis 
and PD.  
P-selectin is produced by both platelets and endothelial cells, and mediates early inflammatory 
cell adhesion. Thus the early elevation of P-selectin may be associated with endothelial 
dysfunction and platelet activation, whereas the later increase may reflect leukocyte invasion 
peaking around 72 hours. Experimental data showed that anti-P-selectin monoclonal antibody 
therapy at permanent middle cerebral artery occlusion decreased the invasion of leukocytes to 
the damaged brain tissue, and decreased the volume of the infarction.  However, since change 
in P-selectin levels correlated with post-stroke infections in our study, it is also possible that 
late elevation indicated leukocyte activation related to an early, subclinical phase of infection.  
The role of IL-6 in stroke is somewhat controversial. Upregulation of IL-6 on neurons, glial 
cells and vascular endothelium is a consistent finding in animal models of cerebral ischemia. 
Although IL-6 is also elevated in the CSF of patients with stroke, its cellular source is unclear: 
it can reflect systemic release and passive passage due to the blood-brain barrier disruption, or 
release from dying neurons and production by microglia. IL-6 on admission correlated with 
concentration of S100B at 72 hours in our cohort, indicating that early systemic production of 
IL-6 correlates with the infarct volume on biomarker levels, similar to neuroimaging studies. 
Higher level of IL-6 after stroke also correlated with early neurological deficit, body 
temperature and long-term poor outcome in previous studies. It is likely that alterations in 
systemic and intrathecal levels of IL-6 may reflect different cellular sources elicited by different 
interactions/pathways, and eventually contribute to the differential effects. Early systemic 
elevation may thus be related to thrombotic events and platelet-endothel-monocyte interactions, 
while late elevation can indicate leukocyte activation. Leukocyte infiltration and local 
activation within the ischemic tissue may be deleterious, but proper systemic activation of 
leukocytes is required to protect against infections in the post-stroke period.  
Similarly, different causes may contribute to elevation of hsCRP at 6 and 72 hours, and late 
increase in concentration may be related to a subclinical infection. This may also explain, why 
an increase of hsCRP by 72 hours correlates with post-stroke infections. Correlation between 
S100B and hsCRP levels may also point to the fact that patients with more extensive infarcts 
are more susceptible to post-stroke infections due to more profound immune dysfunction. 
Several available data show that the presence of post-stroke infections increases the mortality 
of stroke significantly. Therefore it seems logical to use antibiotic prophylaxis in the acute 
phase of ischaemic stroke to prevent infections.  
However, preventive antibiotic trials were controversal. But the STROKE-INF study published 
in 2015 provided II.B. evidence that preventive antibiotic treatment in acute stroke is 
inappropiate. Most probably, not only the pathogenic microorganism itself but other 
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predisposing factors may have a potential role in the development of post-stroke infection. I the 
recent years, a lot of attention have been focused on the role of the innate and humoral immune 
responses, and the CNS injury induced immuno-depression syndrome concept has been 
accepted. 
At present, immunomodulatory therapy is in the centre of interest in acute stroke research 
(Table 5.) 
Table. 5. Studies of immunmodulatory therapies in acute stroke 
Drug Mechanism Stroke onset Duration 
of 
treatment 
Phase Clinical, radiological 
outcome 
Summary 
Enlimomab 
anti-ICAM-1 
monoclonal At 
0-6 h 5 days 
III 
n: 625 
SAE, mRS score 
mortality, infarct volume 
Effective in 
experimental 
stroke, clinical 
trial terminated 
rh IL-1a 
IL-1 receptor 
antagonist 
1-4 months 30 day 
II 
n=34 
Safe, well tolerated, 
decreased the mRS score 
Safe, effective 
Minocyclin 
early modulation of 
inflammatory 
signals 
6-24 h 5 days 
Open-label 
n=152 
Safe, well tolerated, 
decreased the mRS score 
Effective in 
experimental 
stroke, clinical 
trial terminated 
Fingolimod 
sequesters 
lymphocytes in 
lymph nodes, 
preventing an 
autoimmune 
reaction. 
0-4.5 h, 
combined 
with alteplase 
3 days 
Open-label 
n=47 
Safe, well tolerated, 
decreased the mRS score 
and the volume of infarct 
Decreased the 
reperfusional 
injury, improved 
functional 
outcome 
Natalizumab £4-integrin blocker 0-9 h 
single 
dose 
II 
n=200 
NA ongoing 
ICAM-1: intracellular cell adhaesion molecule; rh-IL-1a: recombinant human IL-1 antagonist; SAE: severe 
adverse event; mRS: modified Rankin scale 
In our cohort, the change in the concentration of P-selectin was predictive for forthcoming post-
stroke infection. We contemplate that it may be useful to early identify patients with the highest 
risk for CIDS and infection. These patients may then benefit from novel immunomodulatory 
therapies being currently in the focus of stroke research. 
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IV. THE L-ARGININE PATHWAY IN ACUTE ISCHAEMIC STROKE AND 
SEVERE CAROTID STENOSIS 
 
IV/1. The role of L-arginine metabolites 
Asymmetric-dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are protein 
breakdown products of L-arginine. ADMA directly inhibits endothelial nitric oxide synthase 
(eNOS), thus reduces NO production, whereas SDMA competes with the NO precursor arginine 
for uptake into endothelial cells. Numerous data support the beneficial effect of eNOS and 
vascular NO in the early stages of cerebral ischemia playing a prominent role in maintaining 
cerebral blood flow and preventing neuronal injury. Indeed, eNOS knockout mice show 
decreased blood flow in the ischemic border zone and develop larger cerebral infarctions. 
Although prognostic value of serum concentrations of methylated arginine derivatives has not 
been fully elucidated in stroke, an increase in both ADMA and SDMA plasma levels within the 
first 72 hours after the onset of ischemic stroke may predict poor outcome. 
IV/2. Aims of the study 
The aims of this study were the following: 
(i)  investigation the L-arginine pathway in patients with asymptomatic significant 
carotid stenosis and acute ischemic stroke compared with age-matched healthy controls;  
(ii) longitudinal change of the L-arginine metabolites during the acute phase of acute 
ischemic stroke;  
(iii)  correlation of the L-arginine pathway with biomarkers reflecting infarct size and 
infection; 
(iv) Predictive value of the L-arginine metabolites on death and post-stroke 
infections. 
IV/3. Patients and Methods 
A total of 55 patients suffering from acute ischemic stroke, and 44 patients with asymptomatic 
significant carotid stenosis were prospectively selected for this study. Forty-five age-matched 
healthy blood donors served as normal controls. Medical history concerning previous coronary 
artery disease, chronic obstructive pulmonary disease, diabetes, hypertension, current cigarette 
smoking, serum creatinine levels, and body mass index was obtained from each patient. 
Definitive stroke was defined according to international guidelines. Venous blood samples from 
patients with stroke were taken serially for measurement of ADMA, SDMA, L-arginine, 
hsCRP, and S100 B within 6 hours after the onset of first symptoms, and at 24 and 72 hours. 
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IV/4. Results 
IV/4. a. Baseline levels of metabolites within 6 hours after stroke 
Concentration of all 3 metabolites (L-arginine, ADMA, and SDMA) within 6 hours after the 
onset of ischemic stroke was significantly higher in the sera compared with healthy controls 
and patients with significant carotid stenosis. SDMA was also lower in the sera of patients with 
carotid stenosis and healthy contols. 
IV/4. b. Temporal profile of L-arginine metabolites in acute ischemic stroke 
We investigated changes in the serum concentrations of L-arginine, ADMA, and SDMA within 
6 hours after onset of AIS as well as at 24 and 72 poststroke hours. We observed a slight increase 
in the concentration of L-arginine at 24 hours in contrast to a slight decrease in the levels of 
ADMA; the concentration of SDMA increased continuously. The ratio of L-arginine/ADMA 
was significantly increased at 24 hours and decreased thereafter, whereas we observed a 
decrease in L-arginine/SDMA ratio (Figure 1). 
 
 
Figure 1. Temporal profile of L-arginine and methylarginine derivatives in acute ischemic stroke. Temporal 
profile of L-arginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-
arginine/ADMA and L-arginine/SDMA ratios respectively measured at 6, 24, and 72 poststroke hours. Data are 
presented as mean ± standard deviation. *indicates significantly higher L-arginine/ADMA ratio at 24 hours 
compared with 6 hours. #indicates significantly lower L-arginine/SDMA ratio at 72 hours compared with 6 hours. 
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IV/4. c. Correlation of L-arginine metabolites with S100B protein 
Next, we examined if concentration of metabolites of the L-arginine pathway correlates with 
S100B reflecting infarct size. Concentration of S100B positively correlated with the level of 
SDMA at 72 post-stroke hours. Beside the absolute concentrations, we also investigated 
whether the change of concentration of S100 B within 72 hours showed any correlation with 
changes in the concentration of the 3 metabolites. Although absolute concentrations of ADMA 
did not correlate with the corresponding S100B concentrations, changes in concentration of 
ADMA by 72 hours did show a positive correlation with changes in the concentration of S100B.  
I/4. d. Correlation of L-arginine metabolites with C-reactive protein 
We also examined correlation of the L-arginine pathway with concentration of hsCRP both in 
hyperacute and subacute phase of AIS, as well as in patients with carotid stenosis. 
Concentration of hsCRP within 6 hours after the onset of stroke negatively correlated with L-
arginine levels. Concentration of hsCRP at 72 post-stroke hours positively correlated with the 
level of SDMA. 
IV/4. e. Prediction of death and post-stroke infection 
None of the metabolites of the L-arginine pathway were predictors of death. Multiple logistic 
regression including all variables indicated that changing levels of SDMA and hsCRP were 
predictive for post-stroke infections. 
 
V. Discussion 
We observed that concentrations of all 3 metabolites (L-arginine, ADMA, and SDMA) were 
elevated in the very acute phase of ischemic stroke. An increased basal L-arginine level in 
patients with sichemic stroke might be an adaptive mechanism. L-arginine is the precursor 
molecule for NO, and NO produced by eNOS plays a crucial role in the regulation of vascular 
tone resulting in vasodilation. The extracellular arginine availability may have a beneficial 
influence on cerebral perfusion by increasing NO. It was published in 2013 that increased L-
arginine/ADMA ratio in patients with subarachnoidal hemorrhage correlated with improved 
functional outcome and decreased mortality. Authors suggested that increased blood supply of 
the brain can explain their observations. On the other hand, increased levels of ADMA did not 
correlated with vasospasm detected by transcranial Doppler sonography. They interpreted that 
ADMA causes unfavoruable conditions in the microcirculation. We observed transient 
increasing ratio of L-arginine/ADMA, and this transient elevation of L-arginine may be part of 
compensatory mechanisms, which result in vasodilatation in the damaged brain tissue. 
Experimental data suggested that parenteral L-arginine supplementation increased the eNOS-
dependent cerebral blood perfusion. In our cohort, we found that neither the absolute levels of 
ADMA nor the change in ADMA levels were predictive for stroke outcome and the presence 
of post-stroke infections.  
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Less information is available about the role of SDMA in cardiovascular diseases. In our study, 
the changing concentration of SDMA was predictive for post-stroke infections. It was published 
in 2012 that concentration of SDMA correlated with adverse clinical outcome during the first 
30 days after ischemic stroke. In a large multiethnic population-based cohort, SDMA but not 
ADMA was an independent predictor of cardiovascular mortality. 
Next, we examined the relationship between the L-arginine pathway and 2 biomarkers: (i) S100 
B, which correlates with the size of infarct, and (ii) hsCRP, which is regarded as both an 
atherosclerosis and an infection marker.  
We show that the concentration of L-arginine inversely correlates with the early elevation of 
hsCRP. This may suggest that L-arginine indeed may play a protective role, and low L-arginine 
levels are associated with a higher concentration of hsCRP, a risk factor for stroke. We also 
observed that concentration of S100B reflecting the infarct size correlates positively with 
SDMA at 72 poststroke hours, and change of S100B also positively correlates with 
concentration of ADMA. These data may suggest a relationship between the infarct size and L-
arginine pathway. We also examined the effect of L-arginine pathway on post-stroke infections. 
Change in SDMA concentration by 72 hours was an independent predictor of post-stroke 
infections.  
In short, we can conclude that elevated levels of L-arginine metabolites in the acute phase of 
ischemic stroke indicate enhanced endothelial dysfunction. The early increase in the level of L-
arginine may be an adaptive reaction for this vascular dysfunction. Increasing level of SDMA 
can be also a predictor of forthcoming post-stroke infections.  
It is debatable, whether therapeutic interventions influencing the levels of L-arginine 
metabolites can improve endothelial dysfunction and clinical outcome. Modulators of the L-
arginine pathway are the statins, angiotensin-converting enzyme inhibitors, and isoform-
specific NOS inhibitors. On the other hand, the elevated levels of L-arginine metabolites can 
be also consequences of an irreversible tissue damage. Considering these, further studies are 
required.  
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VI. SUMMARY OF THE THESIS 
  
1. Elevated hsCRP levels in the hyperacute phase of ischaemic stroke correlated with the 
severity of stroke.  
2. Increased concentration of hsCRP 72 hour after stroke correlated with forthcoming post-
stroke infections. 
3. S100B level at 6 and 72 hours reflecting the volume of brain infarct correlated with the 
occurrence of post-stroke infections and mortality. 
4. IL-6 level both at 6 and 72 hours was predictive for unfavourable outcome and post-stroke 
infections.  
5. Changing levels of P-selectin between 6-72 hours was highly predictive for post-stroke 
infection. 
6. The L-arginine, ADMA, SDMA concentrations are elevated in hyperacute phase of stroke 
indicating severe endothelial dysfunction. 
7. L-arginine level (already decreasing) measured at 72- hour and simultaneusly increasing 
SDMA concentrations are early predictors of post-stroke infections.  
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